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Abstract 
Purpose: Eyes fellow to nonischemic central retinal vein occlusion (CRVO) 
were examined for abnormalities, which might explain their increased risk for 
future occlusion, using adaptive optics scanning light ophthalmoscope 
fluorescein angiography. 
Methods: Adaptive optics scanning light ophthalmoscope fluorescein 
angiography foveal microvascular densities were calculated. Nonperfused 
capillaries adjacent to the foveal avascular zone were identified. Spectral 
domain optical coherence tomography, ultrawide field fluorescein 
angiographies, and microperimetry were also performed. 
Results: Ten fellow eyes of nine nonischemic CRVO and 1 nonischemic hemi-
CRVO subjects and four affected eyes of three nonischemic CRVO and one 
nonischemic hemi-CRVO subjects were imaged. Ninety percent of fellow eyes 
and 100% of affected eyes demonstrated at least 1 nonperfused capillary 
compared with 31% of healthy eyes. Fellow eye microvascular density (35 ± 
3.6 mm−1) was significantly higher than that of affected eyes (25 ± 5.2 
mm−1) and significantly lower than that of healthy eyes (42 ± 4.2 mm−1). 
Compared with healthy controls, spectral domain optical coherence 
tomography thicknesses showed no significant difference, whereas 
microperimetry and 2/9 ultrawide field fluorescein angiography revealed 
abnormalities in fellow eyes. 
Conclusion: Fellow eye changes detectable on adaptive optics scanning light 
ophthalmoscope fluorescein angiography reflect subclinical pathology difficult 
to detect using conventional imaging technologies. These changes may help 
elucidate the pathogenesis of nonischemic CRVO and help identify eyes at 
increased risk of future occlusion. 
 
Keywords: adaptive optics, fluorescein angiography, retinal 
microvasculature, image analysis, central retinal vein occlusion, fellow eye 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Retina, Vol 35, No. 10 (october 2015): pg. 2028-2036. DOI. This article is © Lippincott Williams & Wilkins, Inc. and 
permission has been granted for this version to appear in e-Publications@Marquette. Lippincott Williams & Wilkins, Inc. 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from Lippincott Williams & Wilkins, Inc. 
4 
 
Central retinal vein occlusion (CRVO) is a significant cause of 
acquired vision loss with a global prevalence of 0.08%.1 Although a 
number of major and minor systemic risk factors have been 
identified,2–6 a considerable number of patients with CRVO present 
without identifiable risk factors. Thus, despite years of research since 
its first description in 1855,7 its pathogenesis remains poorly 
understood.8,9 
Epidemiologic studies have shown that eyes fellow to unilateral 
CRVO have a significantly increased risk of developing venous 
occlusion compared with the general population.10–12 Previous studies 
have shown that before any occlusion, these fellow eyes are both 
structurally13 and electrophysiologically14 compromised. These findings 
suggest that additional study of fellow eyes may elucidate the early 
pathological changes signaling a future occlusive event. 
The purpose of this study was to assess the perfused foveal 
microvascular density and identify nonperfused capillaries in 
nonischemic CRVO fellow and affected eyes using adaptive optics 
scanning light ophthalmoscope fluorescein angiography (AOSLO FA)15 
and to compare the findings with previously published data on 16 
healthy controls.16 Spectral domain optical coherence tomography 
(SD-OCT), ultrawide field fluorescein angiography (UWFFA), and 
microperimetry—standard clinical modalities for studying retinal 
structure and function—were also performed. 
Methods 
Subject Recruitment 
This study followed the tenets of the Declaration of Helsinki and 
was approved by the New York Eye and Ear Infirmary Institutional 
Review Board. Written informed consent was obtained from each 
participant after the nature, and potential risks of the study were 
explained. Retrospective chart review was performed to identify 
subjects for imaging. Inclusion criteria included a best-corrected visual 
acuity (BCVA) of ≥20/60 with good central fixation, pupil dilation of at 
least 5 mm, normal anterior segment with clear crystalline lens, clear 
media, and minimal or no inner retinal edema at the fovea as 
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determined using SD-OCT (Heidelberg Spectralis HRA+OCT; 
Heidelberg Engineering Inc, Heidelberg, Germany). Ten fellow eyes of 
9 nonischemic CRVO and 1 superior nonischemic hemi-CRVO subjects 
(BCVA ≥20/25; mean age: 45 years; range: 27–67; Table 1) and 4 
affected eyes of 3 nonischemic CRVO and 1 superior nonischemic 
hemi-CRVO subjects (BCVA ≥20/25 – 2; mean age: 50 years; range: 
39–64; Table 2) were imaged. Medical histories were reviewed and 
fellow eyes with any preexisting retinopathy were excluded. All 
subjects underwent a single imaging session. Previously published 
data from 16 healthy eyes were used for comparison.16 The 16 healthy 
adults included 8 men and 8 women with a mean age of 25 years 
(range: 21–29). They had no significant medical or surgical history 
with normal ocular examination and intraocular pressures and a BCVA 
of 20/20 or better in each study eye. 
Table 1. Demographic of Nonischemic CRVO fellow Eye Patients 
 
Subject 
ID 
Age and 
Sex 
Medical/Social History Medications Family 
History 
Ophthalmic 
History 
Time 
Since 
RVO 
RR_0161 67-year-
old 
woman 
HL, elevated sugars Lovastatin, 
Aspirin 
Father: HL CRVO OS 2 years 
RR_0182 55-year-
old man 
None None Mother: HL; 
father: DM, 
HTN; brother: 
DM 
CRVO OD 1.5 years 
RR_0235 39-year-
old man 
None None Mother: DM, 
HTN, HL; 3/7 
siblings: DM 
Hemi-CRVO OD 7 months 
RR_0239 27-year-
old man 
0.5 PPD for 5 years, quit 
6 years ago. 
None Not taken CRVO OD 1 week 
RR_0273 46-year-
old 
woman 
Sedentary lifestyle None None Both parents: 
DM 
CRVO OD 5.5 years 
RR_0289 44-year-
old man 
Borderline HTN None Father: DM CRVO OD 2 years 
RR_0298 33-year-
old 
woman 
None None None CRVO OS 4 years 
RR_0299 37-year-
old 
woman 
Anemia Iron Mother: HTN CRVO OS 1 year 
RR_0300 50-year-
old 
woman 
Heavy drinking (12–24 
beers/week). Quit 1 year 
ago 
Multivitamin Both parents: 
DM, HTN; 
sister: DM 
CRVO OS 4 years 
DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension; PPD, packs per day. 
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Table 2. Demographic of Nonischemic CRVO Affected Eye 
Patients 
Subject 
ID 
Age and 
Sex 
Medical 
History Medications 
Family 
History 
Ophthalmic 
History 
Time 
Since 
RVO 
Treatment 
History 
BCVA-
Affected 
Eye 
RR_0149 43-year-
old man 
None None Heart 
disease 
CRVO OD 5 years IBI × 2; 2 
years* 
20/25 + 2 
RR_0151 64-year-
old 
woman 
Bipolar 
disorder 
Valproic acid, 
Risperidone 
None CRVO OS 1.5 
years 
IBI × 8; 5 
months* 
20/20 
RR_0182 55-year-
old man 
None None Mother: HL; 
father: DM, 
HTN; 
brother: DM 
CRVO OD 1.5 
years 
IBI × 4; 1 
year* 
20/25 – 2 
RR_0235 39-year-
old man 
None None Mother: DM, 
HTN, HL; 3/7 
siblings: DM 
Hemi-CRVO 
OD 
7 
months 
IBI × 1; 5 
months* 
20/20 
*Elapsed time between last IBI and AOSLO FA. 
DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension; IBI, intravitreal 
bevacizumab injection. 
Clinical Imaging 
Charts of the 10 fellow eyes were reviewed for intraocular 
pressure readings, measured with either applanation tonometry or 
Tono-Pen (Tono-Pen XL and AVIA; Reichert Inc, New York, NY) near 
the date of imaging. Before imaging, mydriasis and cycloplegia were 
induced using 2.5% phenylephrine hydrochloride ophthalmic solution 
(Bausch & Lomb Inc, Tampa, FL) and 1% tropicamide ophthalmic 
solution (Akorn Inc, Lake Forest, IL). Axial lengths were measured in 
all eyes (IOL Master; Carl Zeiss Meditec AG, Jena, Germany) to size 
the AOSLO image scale in micrometers per pixel using the Emsley 
schematic eye model.17 
Spectral domain optical coherence tomography imaging and 
analysis  
Spectral domain optical coherence tomography imaging was 
performed on each of the 10 fellow eyes, using 12 radial scans at 15° 
intervals through the center of the fovea. Each scan spanned 20° and 
was an average of 9 frames. Each radial scan was manually 
segmented to delineate the inner limiting membrane, outer plexiform 
layer/outer nuclear layer interface, and the retinal pigment 
epithelium/choroid interface. A spline algorithm was used to 
interpolate between sample points marked on the inner limiting 
membrane, outer plexiform layer/outer nuclear layer interface, and 
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retinal pigment epithelium/choroid interface to measure the inner 
retinal thickness and total retinal thickness (TRT). Inner retinal 
thickness and TRT each represented means of 144 data points per 
eye—12 data points per SD-OCT radial scan at 250, 350, 450, 550, 
650, and 750 μm radial distance from foveal center in both directions, 
times 12 SD-OCT radial scans through the foveal center per eye. Then, 
IRT/TRT ratios were calculated per fellow eye and compared with 
respective previously acquired data from 16 healthy eyes. 
Microperimetry  
Microperimetry was performed on fellow eyes after AOSLO FA 
imaging using a Polar 3 pattern of 28 test points, Goldmann Size III 
stimuli with duration of 200 milliseconds at 1.5-second intervals, and a 
4-2 threshold algorithm (OPKO SD-OCT/SLO with add-on 
Microperimetry module; OPKO, Miami, FL). Previously published data 
from 169 healthy eyes were used for comparison.18 The 169 healthy 
adults included 71 men and 98 women with a mean age of 48 years 
(range: 21–85). They had no significant medical history with normal 
ocular examination and intraocular pressures and a BCVA of 20/25 or 
better in each study eye. 
Ultrawide field fluorescein angiography  
All UWFFAs were performed with intravenous fluorescein 
administration. Patient records were reviewed for recently performed 
UWFFA (Optos, Marlborough, MA) on the fellow eyes (within 3 years of 
AOSLO FA imaging). Ultrawide field fluorescein angiography was 
acquired for patients without previous studies. Late-phase UWFFA 
images of the fellow eyes were assessed by two retina specialists for 
abnormalities. 
Adaptive Optics Scanning Light Ophthalmoscope 
Fluorescein Angiography Imaging and Analysis 
The AOSLO machine was a replica of the one built by Dubra and 
Sulai,19 modified for AOSLO FA as described by Pinhas et al.15 Adaptive 
optics scanning light ophthalmoscope fluorescein angiography imaging 
and image processing were performed as described by Pinhas et al.16 
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Fluorescein was administered orally for AOSLO FA imaging to allow for 
a longer imaging window. Simultaneous 1.75° field-of-view infrared 
(IR) confocal reflectance (790 nm) and fluorescence (488 nm) image 
sequences were acquired approximately 10 minutes after oral 
fluorescein administration. The fluorescence channel was focused on 
the superficial layers of retinal microvasculature, and the IR 
reflectance channel was focused on the photoreceptors. A square 
region of approximately 6° × 6° in size centered at the fovea was 
imaged. A set of images using the IR channel covering a 2.5° × 2.5° 
region around the fovea focused on the superficial layers of retinal 
microvasculature was also acquired. All sources were treated as lasers 
for the purposes of maximum permissible exposure calculations. Light 
exposure was determined to be 6 times below both the photochemical 
and thermal maximum permissible exposure limits according to the 
American National Standards Institute (ANSI) Z136.20 
Respective registered averaged images with high signal-to-noise 
ratio were stitched together to create larger IR structural and FA 
perfusion maps (Adobe Photoshop CS6; Adobe Systems, Inc, San 
Jose, CA). Comparison of the IR structural with the FA perfusion maps 
revealed nonperfused capillaries adjacent to the foveal avascular zone 
(Figure 1, A and B). Circular FA perfusion maps centered on the fovea 
with a radius of 800 μm were skeletonized in a semiautomated fashion 
using a custom-developed MATLAB GUI program (Mathworks, Inc, 
Natick, MA), as previously described.16 The skeletonized perfusion 
maps were then divided into equiangular octants and 8 consecutive 
annuli with a 100-μm radial step-size, creating 64 regions of interest 
(Figure 2, A–C). Microvascular density was calculated per region of 
interest, and individual region of interest values were grouped into 
annulus, octant, and eye means, which were further averaged per 
study group. In calculating mean microvascular densities per eye, the 
central 400 μm was excluded to avoid the effect of substantial foveal 
avascular zone diameter variation across individuals. 
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Fig. 1. A. Fluorescein angiography perfusion map of RR_0289 fellow eye (left eye), 
showing foveal avascular zone and surrounding capillaries. B. Corresponding IR 
structural map. Arrows indicate non-perfused capillaries. 
 
 
Fig. 2. A. Fluorescein angiography (FA) perfusion map of RR_0289 fellow eye (left 
eye). B. Corresponding skeletonized FA perfusion map with (C) octant and annulus 
grid overlay. D. Colorized density contour map. S, superior; SN, superior nasal; N, 
nasal; IN, inferior nasal; I, inferior; IT, inferior temporal; T, temporal; ST, superior 
temporal. 
A separate algorithm created colorized density contour maps by 
computing microvascular density within each 16 × 16-μm sampling 
window with 8-μm overlaps over the skeletonized perfusion maps 
using the built-in MATLAB function blkproc. These maps provided a 
more easily interpretable graphic representation of regional 
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microvascular density variations across the FA perfusion maps (Figure 
2D). 
Results 
Under the assumption of normally distributed variables, IRT/TRT 
ratios, microperimetry, and microvascular density group averages ± 
SD values were compared for significant differences using an unpaired 
2-tailed t-test with a P value of <0.05. 
All 10 fellow eyes had intraocular pressures ≤21 mmHg. 
Spectral domain optical coherence tomography average IRT/TRT ratio 
of the 10 fellow eyes was lower than that of healthy eyes; however, 
this difference was not quite statistically significant (0.37 ± 0.04 vs. 
0.39 ± 0.04; t(24) = 1.2, P = 0.23). Microperimetry average 
sensitivity of the 10 fellow eyes (17 ± 1.4, range: 12–20 dB) was 
significantly lower compared with previously reported normative data 
(18 ± 1.2, range: 13–20 dB)18; t(177) = 2.5, P = 0.0120. Previous 
records of UWFFA were available for 7 fellow eye patients within 3 
years before AOSLO FA imaging, and UWFFA was acquired within 3 
months after AOSLO FA for 2 fellow eye patients. RR_0273 was lost to 
follow-up before we were able to obtain UWFFA images. On 
assessment, RR_0235 showed leakage at a terminal branch of the 
superotemporal arcade and RR_0289 showed a few central and 
peripheral microaneurysms (Figure 3, A and B). Ultrawide field 
fluorescein angiography was within normal limits for the rest of the 7/9 
fellow eyes. 
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Fig. 3. Examples of fellow eye angiopathy discovered on ultrawide field fluorescein 
angiography. A. RR_0235 left eye showed leakage at a terminal branch of the 
superotemporal arcade. B. RR_0289 left eye showed a few central and peripheral 
microaneurysms (arrows).  
Comparing AOSLO IR structural and FA perfusion maps allowed 
detection of at least 1 nonperfused capillary segment in 90% of the 10 
fellow eyes (Figure 1, A and B) and 100% of the 4 affected eyes, 
compared with a 31% rate found in the 16 healthy eyes. Average 
microvascular density ± SD of the 10 fellow eyes was 35 ± 3.6 mm−1 
(range: 30–41 mm−1), significantly lower than that of the 16 healthy 
eyes (42 ± 4.2 mm−1; range: 33–50 mm−1; t(24) = 4.4, P = 0.0002) 
and significantly higher than that of the 4 nonischemic CRVO-affected 
eyes (25 ± 5.2 mm−1; range: 18–30 mm−1; t(12) = 4.2, P = 0.0013) 
(Table 3; Figure 4, A and B). Figures 5 and and66 are 2 examples of 
FA perfusion and colorized density contour maps, each showing an 
affected and fellow eye pair compared with a representative healthy 
eye. The unaffected octants of the nonischemic hemi-CRVO– affected 
eye resembled fellow eyes in microvascular density values (Table 2; 
Figure 6). 
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Fig. 4. A. Scatter plot of microvascular density values of fellow eyes (n = 10), 
compared with healthy (n = 16) and affected eyes (n = 4). Microvascular density 
values are presented per eye as averages of annuli 300–800. Black bars indicate 
group averages. B. An annulus comparison of microvascular densities of the 3 groups. 
Error bars represent SD. Asterisks indicate significant differences (unpaired t-test with 
P < 0.05) between healthy and fellow eyes (blue asterisks) and affected and fellow 
eyes (green asterisks) in microvascular densities at a given annulus. 
 
 
Fig. 5: RR0182-affected eye (nonischemic central retinal vein occlusion in the right 
eye) and fellow eye (left eye) compared with a healthy control eye, with fluorescein 
angiography (FA) perfusion maps and corresponding colorized density contour maps. 
Subject age, sex, eye imaged, and perfused foveal microvascular density (mean of 
annuli 300–800) appear in the lower left corner of respective FA perfusion maps. 
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Fig. 6. RR0235-affected eye (nonischemic superior hemiretinal vein occlusion in the 
right eye) and fellow eye (left eye) compared with a healthy control eye, with 
fluorescein angiography (FA) perfusion maps and corresponding colorized density 
contour maps. Subject age, sex, eye imaged, and perfused foveal microvascular 
density (mean of annuli 300–800) appear in the lower left corner of respective FA 
perfusion maps. 
 
Table 3. Microvascular Density Results 
Eyes Microvascular Density ± SD (mm−1) 
Healthy eyes (n = 16) 42 ± 4.2  
Affected eyes (n = 4) 25 ± 5.2  
Fellow eyes (n = 10) 35 ± 3.6  
Superior hemi-CRVO eye (n = 1) SN, S, ST 18 
 IN, I, IT 34 
Fellow eye microvascular densities were significantly lower than the 16 healthy eyes 
and significantly higher than the 4 affected eyes. Unaffected octants of the 
nonischemic superior hemi-CRVO–affected eye had density values similar to fellow 
eyes. 
I, inferior; IN, inferior nasal; IT, inferior temporal; N, nasal; S, superior; SN, superior 
nasal; ST, superior temporal; T, temporal. 
Discussion 
Spectral domain optical coherence tomography average IRT/TRT 
ratios were not significantly different between healthy and fellow eyes. 
Seven of nine of the fellow eyes did not have signs of vascular 
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compromise on UWFFA. Fellow eye sensitivity on microperimetry was 
on the lower side of normal but remained within clinically acceptable 
levels. Adaptive optics scanning light ophthalmoscope fluorescein 
angiography revealed an increased number of non-perfused capillaries 
near the foveal avascular zone and decreased perfused foveal 
microvascular density in fellow eyes, compared with healthy data. 
Microvascular compromise may directly cause previously documented 
fellow eye structural and functional abnormalities13,14; however, with 
the current limited data, the sequence of events remains uncertain. 
Using current knowledge of pathophysiology, we attempt to 
explain why eyes fellow to nonischemic CRVO may show decreased 
foveal microvascular density. The major risk factors for CRVO have 
been identified as increasing age, hypertension, diabetes, 
arteriosclerotic vascular risk factors (i.e., hyperlipidemia), and 
glaucoma.9 Although there are marked differences in the pathogenesis 
of each risk factor, it has been shown that subclinical inflammation 
with the production of reactive oxygen species is an early shared 
pathogenic step.21–31 Thus, even before clinically evident disease, 
inflammation and reactive oxygen species can cause direct damage to 
the endothelium and lead to capillary closure. Furthermore, the 
increased expression of adhesion molecules during inflammation 
causes leukostasis, which can cause physical obstruction of capillary 
lumens resulting in nonperfusion.32 Dehydration and hypercoagulability 
disorders, additional CRVO risk factors,6 may also lead to capillary 
nonperfusion. The subclinical nature of these changes preceding 
clinical disease may explain why the majority of our fellow eye 
subjects did not report any of the known risk factors for CRVO, yet had 
a history of nonischemic CRVO in 1 eye and decreased microvascular 
density in the fellow eye. 
Decreased microvascular density observed in fellow eyes may 
be a predictor of increased risk of future occlusion. The same 
processes that cause damage to the microvascular endothelium may 
affect larger vessels, leading to injury accumulation in the central 
retinal vasculature and ultimately CRVO. Another possibility is an 
acute-on-chronic mechanism where the chronic subclinical 
development of capillary non-perfusion leads to local tissue hypoxia 
and an increase in the production of reactive factors, such as 
endothelin-1 (vasoconstriction) and vascular endothelial growth factor 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Retina, Vol 35, No. 10 (october 2015): pg. 2028-2036. DOI. This article is © Lippincott Williams & Wilkins, Inc. and 
permission has been granted for this version to appear in e-Publications@Marquette. Lippincott Williams & Wilkins, Inc. 
does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from Lippincott Williams & Wilkins, Inc. 
15 
 
(vessel permeability).33 Fraenkl et al have proposed that elevated 
concentrations of these factors can lead to the clinical picture of 
CRVO— a functional constriction of the vein, edema, and 
hemorrhage.33 
There are some noted limitations of this preliminary study 
besides the small sample size. Because increasing age is itself a risk 
factor for CRVO that may cause decreased microvascular density, we 
believe that it was appropriate to compare nonischemic CRVO fellow 
eye results with non–age-matched healthy controls in their 20s. 
However, future studies should include a larger sample size and 
control for age. Another limitation of this study was that the medical 
histories collected from all subjects were self-reported. Most of our 
nonischemic CRVO subjects reported having undergone an extensive 
workup for the reason of occlusion that was inconclusive. Future 
studies with larger sample sizes should include a more comprehensive 
collection of blood pressure history, hemoglobin A1c, and lipid panel 
trends. Another limitation of this study was that all of the nonischemic 
CRVO-affected eyes had undergone treatment with intravitreal 
bevacizumab. This treatment likely slowed or may have even reversed 
the natural course of microvascular disease, limiting our comparison of 
affected eye data with fellow and healthy eye data. 
There were a few notable limitations in acquisition of 
conventional images. The fact that a number of the UWFFAs were not 
performed near the time of AOSLO FA limits any statement of 
sensitivity of this modality for detecting subclinical pathology. Also, 
because microperimetry was performed in most cases immediately 
after AOSLO FA, microperimetry sensitivity may have on average been 
lower because of temporary bleaching of retina by blue light used in 
AOSLO FA. 
Future prospective studies of the retinal microvasculature may 
be able to more fully determine the role of these anatomic changes in 
the pathogenesis of venous occlusion. The ability to study these 
phenomena at the capillary level over time may provide many 
additional insights into microvascular changes that have previously 
been unavailable because of limitations of our clinical imaging tools. 
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